Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Clinical and Translational Research in Head and Neck Cancer
share announcement

Clinical and Translational Research in Head and Neck Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 8588

Special Issue Editor

Dr. Young J. Kim

E-Mail
Guest Editor
Chair Oncology, Global Development Scientific Council, Regeneron Pharmaceuticals, New York, NY, USA
Interests: cancer immunology; tumor microenvironment; immune oncology

Special Issue Information

Dear Colleagues,

Head and neck cancer encompass multiple histologic tumors that can represent the breadth of most human cancer, and their unique occurrences in the face/scalp and the upper digestive tracts to include the sinonasal tracts, oral cavity, oropharynx, larynx, and cervical esophagus provide unique challenges for scientists and clinicians. Although there are now new approved drugs for many of these tumor types, there are still important clinical concerns for weighing oncologic cure and functional preservation. Hence, incorporation of a new modalities, such as immunotherapy and targeted biologics, will require basic, clinical, and translational research for optimal patient care that incorporates locoregional recurrence, overall survival, and quality of life maintenance. This Special Issue presents some of these recent advances in oncologic therapeutics in head and neck cancer patients to promote future translational and clinical studies.

Dr. Young J. Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • immunotherapy
  • translation
  • combinatorial clinical trials
  • oncologic therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 1640 KiB  
Article
Targeting Anterior Commissure Involvement with Hyperfractionated Radiotherapy for T1–T2 Squamous Cell Carcinoma of the Glottic Larynx
by Satoshi Seno, Kazuma Iwashita, Akifumi Kajiwara, Rie Sasaki, Tatsuya Furukawa, Masanori Teshima, Hirotaka Shinomiya, Naomi Kiyota, Rod Lynch, Kenji Yoshida, Takeaki Ishihara, Daisuke Miyawaki, Ken-ichi Nibu and Ryohei Sasaki
Cancers 2024, 16(10), 1850; https://doi.org/10.3390/cancers16101850 - 12 May 2024
Viewed by 1133
Abstract
Anterior commissure is involved in about 20% of early-stage glottic squamous cell carcinomas (EGSCCs). Treatment outcomes and prognostic factors for EGSCC with anterior commissure involvement (ACI) were evaluated by focusing on hyperfractionated radiotherapy (74.4 Gy in 62 fractions). One-hundred and fifty-three patients with [...] Read more.
Anterior commissure is involved in about 20% of early-stage glottic squamous cell carcinomas (EGSCCs). Treatment outcomes and prognostic factors for EGSCC with anterior commissure involvement (ACI) were evaluated by focusing on hyperfractionated radiotherapy (74.4 Gy in 62 fractions). One-hundred and fifty-three patients with T1–T2 EGSCC were included in this study. The median total doses for T1a, T1b, and T2 were 66, 74.4, and 74.4 Gy, respectively. Overall, 49 (32%) patients had T1a, 38 (25%) had T1b, and 66 (43%) had T2 disease. The median treatment duration was 46 days. The median follow-up duration was 5.1 years. The 10-year overall and cause-specific survival rates were 72% and 97%, respectively. The 10-year local control rates were 94% for T1a, 88% for T1b, and 81% for T2 disease. Local control rates in patients with ACI were slightly better than those in patients without ACI with T1a and T1b diseases; however, the difference was not significant. The 10-year laryngeal preservation rate was 96%. Six patients experienced grade 3 mucositis, and four patients had grade 3 dermatitis. Hyperfractionated radiotherapy was effective for T1 disease with ACI, but insufficient for T2 disease with ACI. Our treatment strategy resulted in excellent laryngeal preservation. Full article
(This article belongs to the Special Issue Clinical and Translational Research in Head and Neck Cancer)
►▼ Show Figures

Figure 1

12 pages, 1507 KiB  
Article
The Perfect Timing—Immediate versus Delayed Microvascular Reconstruction of the Mandible
by Daniel G. E. Thiem, Fabia Siegberg, Shankeeth Vinayahalingam, Sebastian Blatt, Maximilian Krüger, Bernd Lethaus, Bilal Al-Nawas, Rüdiger Zimmerer and Peer W. Kämmerer
Cancers 2024, 16(5), 974; https://doi.org/10.3390/cancers16050974 - 28 Feb 2024
Viewed by 1126
Abstract
In this retrospective study, the clinical and economic implications of microvascular reconstruction of the mandible were assessed, comparing immediate versus delayed surgical approaches. Utilizing data from two German university departments for oral and maxillofacial surgery, the study included patients who underwent mandibular reconstruction [...] Read more.
In this retrospective study, the clinical and economic implications of microvascular reconstruction of the mandible were assessed, comparing immediate versus delayed surgical approaches. Utilizing data from two German university departments for oral and maxillofacial surgery, the study included patients who underwent mandibular reconstruction following continuity resection. The data assessed included demographic information, reconstruction details, medical history, dental rehabilitation status, and flap survival rates. In total, 177 cases (131 male and 46 females; mean age: 59 years) of bony free flap reconstruction (72 immediate and 105 delayed) were included. Most patients received adjuvant treatment (81% with radiotherapy and 51% combined radiochemotherapy), primarily for tumor resection. Flap survival was not significantly influenced by the timing of reconstruction, radiotherapy status, or the mean interval (14.5 months) between resection and reconstruction. However, immediate reconstruction had consumed significantly fewer resources. The rate of implant-supported masticatory rehabilitation was only 18% overall. This study suggests that immediate jaw reconstruction is economically advantageous without impacting flap survival rates. It emphasizes patient welfare as paramount over financial aspects in clinical decisions. Furthermore, this study highlights the need for improved pathways for masticatory rehabilitation, as evidenced by only 18% of patients with implant-supported dentures, to enhance quality of life and social integration. Full article
(This article belongs to the Special Issue Clinical and Translational Research in Head and Neck Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

28 pages, 5023 KiB  
Review
Role of 18F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications
by Carmelo Caldarella, Marina De Risi, Mariangela Massaccesi, Francesco Miccichè, Francesco Bussu, Jacopo Galli, Vittoria Rufini and Lucia Leccisotti
Cancers 2024, 16(10), 1905; https://doi.org/10.3390/cancers16101905 - 16 May 2024
Cited by 2 | Viewed by 2129
Abstract
This article provides an overview of the use of 18F-FDG PET/CT in various clinical scenarios of head–neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. [...] Read more.
This article provides an overview of the use of 18F-FDG PET/CT in various clinical scenarios of head–neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. Methodological aspects and the most frequent pitfalls in head–neck imaging interpretation are described. In the initial work-up, 18F-FDG PET/CT is recommended in patients with metastatic cervical lymphadenectomy and occult primary tumor; moreover, it is a well-established imaging tool for detecting cervical nodal involvement, distant metastases, and synchronous primary tumors. Various 18F-FDG pre-treatment parameters show prognostic value in terms of disease progression and overall survival. In this scenario, an emerging role is played by radiomics and machine learning. For radiation-treatment planning, 18F-FDG PET/CT provides an accurate delineation of target volumes and treatment adaptation. Due to its high negative predictive value, 18F-FDG PET/CT, performed at least 12 weeks after the completion of chemoradiotherapy, can prevent unnecessary neck dissections. In addition to radiomics and machine learning, emerging applications include PET/MRI, which combines the high soft-tissue contrast of MRI with the metabolic information of PET, and the use of PET radiopharmaceuticals other than 18F-FDG, which can answer specific clinical needs. Full article
(This article belongs to the Special Issue Clinical and Translational Research in Head and Neck Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

12 pages, 945 KiB  
Systematic Review
Systematic Review of Nutrition Interventions to Improve Short Term Outcomes in Head and Neck Cancer Patients
by Claire Leis, Anna E. Arthur, Xin Chen, Michael W. Greene and Andrew D. Frugé
Cancers 2023, 15(3), 822; https://doi.org/10.3390/cancers15030822 - 29 Jan 2023
Cited by 5 | Viewed by 3310
Abstract
Head and neck cancer (HNC) is associated with high rates of malnutrition. We conducted a systematic review and descriptive analysis to determine the effects of nutrition interventions on the nutrition status, quality of life (QOL), and treatment tolerance of HNC patients. PubMed, Web [...] Read more.
Head and neck cancer (HNC) is associated with high rates of malnutrition. We conducted a systematic review and descriptive analysis to determine the effects of nutrition interventions on the nutrition status, quality of life (QOL), and treatment tolerance of HNC patients. PubMed, Web of Science, and Embase were searched to include all potentially relevant studies published between 2006–2022. Meta-analysis was not conducted due to heterogeneity of study designs and outcomes reported. Studies were categorized as nutrition interventions: (1) with oral nutrition supplements (ONS) and medical nutrition therapy (MNT) delivered by an RD; (2) with enteral nutrition (EN) support and MNT delivered by an RD; (3) with motivational interviewing and no ONS or EN; and (4) with ONS and no RD. Seven articles met inclusion criteria. Studies measured outcomes from immediately following treatment to 12 months post-treatment. Interventions resulted in benefits to lean mass/weight maintenance (three studies), QOL (two studies), nutrient intake adequacy (one study) and treatment tolerance (two studies). Nutrition counseling by a registered dietitian leads to improved nutrition status and QOL. Further research is needed to determine best practices related to timing of initiation, duration of nutrition intervention, as well as frequency of dietitian follow-up. Full article
(This article belongs to the Special Issue Clinical and Translational Research in Head and Neck Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop